IRAK1 (Thr209) Polyclonal Antibody

Applications

  • WB
  • FCM
  • IHC-P
  • IF(ICC)

Reactivity

  • Human
  • Mouse
  • Rat
Overview
Catalog # bs-3193R
Product Name IRAK1 (Thr209) Polyclonal Antibody
Applications WB, FCM, IHC-P, IF(ICC)
Specificity This phosphorylation site is homologous to Thr209 in Mouse and Rat.
Reactivity Human, Mouse, Rat
Specifications
Conjugation Unconjugated
Host Rabbit
Source KLH conjugated synthetic phosphopeptide derived from human IRAK1 around the phosphorylation site of Thr209 [RG(p-T)HN]
Modification Site Thr209
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.
Storage Condition Store at -20°C for 12 months..
Target
Gene ID 3654
Swiss Prot P51617
Subcellular location Cytoplasm, Nucleus
Synonyms IRAK; pelle; Interleukin-1 receptor-associated kinase 1; IRAK-1; IRAK1
Background Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates the interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes, which drive the cell in an antiviral state. When sumoylated, translocates to the nucleus and phosphorylates STAT3.
Application Dilution
WB 1:300-1000
FCM 1:20-100
IHC-P 1:200-400
IF(ICC) 1:50-200